Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817219 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris
A Phase 2 study of Psoriasis Vulgaris, sponsored by LEO Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 8
- Study locations
NCT00817219 is a Phase 2 study of Psoriasis Vulgaris that has completed, run by LEO Pharma. The registered enrollment target is 33 participants, below the 87-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (62% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT00817219, a Phase 2 study of Psoriasis Vulgaris, has completed, sponsored by LEO Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of 4 weeks of TACLONEX ointment in adolescent patients with psoriasis vulgaris.
Conditions Studied
Interventions
- DRUG Calcipotriene plus betamethasone dipropionate ointment
Study Locations (8)
California
- Center for Dermatology Clinical Research - Fremont
- University of California at San Diego/Rady Children's Hospital - San Diego
Texas
- Arlington Research Center - Arlington
- University of Texas-Dermatology - Houston
Florida
- Ameriderm Research - Maitland
Illinois
- Northwestern University's Feinberg School of Medicine - Chicago
Virginia
- Virginia Clinical Research, Inc. - Norfolk
Washington
- DBA Dermatology Associates - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00817219
The ClinicalTrials.gov registry entry for NCT00817219 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 87-participant average among 6 other Psoriasis Vulgaris trials with a reported enrollment target (62% lower). The listed sponsor is LEO Pharma, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psoriasis Vulgaris appearing as the primary indexed condition, and to 1 intervention - of which Calcipotriene plus betamethasone dipropionate ointment is the first listed.
NCT00817219 reports 8 study locations spanning 6 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT00817219 about?
NCT00817219 is a clinical study titled "Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris". The purpose of this study is to evaluate the safety and efficacy of 4 weeks of TACLONEX ointment in adolescent patients with psoriasis vulgaris.
What is the current status of trial NCT00817219?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2009-07. Estimated completion is 2011-12.
What conditions does trial NCT00817219 study?
This clinical trial studies the following conditions: Psoriasis Vulgaris.
What interventions are being tested in trial NCT00817219?
The interventions under investigation include: Calcipotriene plus betamethasone dipropionate ointment (DRUG).
Who is sponsoring clinical trial NCT00817219?
This trial is sponsored by LEO Pharma, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00817219 being conducted?
This trial has 8 study locations across California, Florida, Illinois, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis Vulgaris
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
COMPLETED · Phase 2
-
Correction of Psoriatic T Cell Signatures by Deucravacitinib
RECRUITING · Phase 4
-
Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)
RECRUITING · Phase 3
-
Use of Botulinum Toxin to Treat Psoriasis
COMPLETED · Phase 1
-
Blue Light Phototherapy
COMPLETED · NA
-
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.